Journals / Dahili ve Cerrahi Bilimler Yoğun Bakım Dergisi / 2018 / Cilt: 9 - Sayı: 1

Drug Use in Continuous Renal Replacement Therapy and the Comparison of Electronic Drug Information Resources for Dose Adjustments

Sürekli Renal Replasman Tedavisinde İlaç Kullanımı ve Doz Ayarlaması İçin Kullanılan Elektronik İlaç Bilgi Kaynaklarının Karşılaştırılması

Pages
7–11
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The optimal drug regimen should be confirmed by using different resources, and the patient’s clinical response should be closely monitored.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Continuous renal replacement therapy (CRRT) is frequently used for critically ill patients with acute renal failure.
📊
Key Findings & Data:Material and Methods: Electronic drug information sources [The Sanford Guide to Antimicrobial Therapy, Micromedex®, Kidney Disease Program (KDP), Medscape, and UpToDate®] were reviewed by clinical pharmacists in order to compare CRRT-related recommendations for 25 most frequently used antimicrobial drugs (ampicillin, piperacillin/ tazobactam, ceftriaxone, cefepime, cefotaxime, meropenem, trimethoprim/sulfamethoxazole, clarithromycin, tigecycline, ciprofloxacin, moxifloxacin, amikacin, vancomycin, teicoplanin, colistin, metronidazole, amphotericin B, caspofungin, anidulafungin, fluconazole, voriconazole, posaconazole, acyclovir, ganciclovir, and oseltamivir) in Hacettepe University Hospitals Medical Intensive Care Units.
💡
Conclusion & Impact:The optimal drug regimen should be confirmed by using different resources, and the patient’s clinical response should be closely monitored.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Continuous renal replacement therapy (CRRT) is frequently used for critically ill patients with acute renal failure. However, information on drug dosing in CRRT is limited; therefore, electronic resources of information are generally used. The aim of this study is to compare the dosing recommendations provided by five different commonly used electronic drug information resources regarding dose adjustments for the antimicrobial drugs used in CRRT. Material and Methods: Electronic drug information sources [The Sanford Guide to Antimicrobial Therapy, Micromedex®, Kidney Disease Program (KDP), Medscape, and UpToDate®] were reviewed by clinical pharmacists in order to compare CRRT-related recommendations for 25 most frequently used antimicrobial drugs (ampicillin, piperacillin/ tazobactam, ceftriaxone, cefepime, cefotaxime, meropenem, trimethoprim/sulfamethoxazole, clarithromycin, tigecycline, ciprofloxacin, moxifloxacin, amikacin, vancomycin, teicoplanin, colistin, metronidazole, amphotericin B, caspofungin, anidulafungin, fluconazole, voriconazole, posaconazole, acyclovir, ganciclovir, and oseltamivir) in Hacettepe University Hospitals Medical Intensive Care Units. Results: The Sanford Guide to Antimicrobial Therapy, KDP, and UpToDate® included detailed information and/or recommendations regarding drug dosing in CRRT compared to Micromedex® and Medscape. Dosing recommendations according to the CRRT type were only listed in Micromedex® and UpToDate® databases. The Sanford Guide to Antimicrobial Therapy, Micromedex®, KDP, and UpToDate® contained references about recommendations for some of the antimicrobial drugs. The differences in recommendati ons of electronic resources were detected particularly for piperacillin/tazobactam, trimethoprim/sulfamethoxazole, amikacin, vancomycin, colistin, and voriconazole. Conclusion: The dosing recommendations for drug use in CRRT available at one particular electronic resource should not be considered as “one size fits all”. There are few studies evaluating the dosing of antimicrobial drugs for patients receiving CRRT, and variations in recommendations exist among the information sources. The optimal drug regimen should be confirmed by using different resources, and the patient’s clinical response should be closely monitored.

Özet

Amaç: Sürekli renal replasman tedavisi (SRRT), akut böbrekhasarı gelişen kritik hastalarda sıklıkla kullanılmaktadır; ancak,SRRT’de ilaç dozlaması ile ilgili bilgi kaynakları sınırlıdırve genellikle elektronik bilgi kaynaklarına başvurulmaktadır.Bu çalışmada SRRT’de ilaç dozunun ayarlanması amacıylayaygın olarak kullanılan beş elektronik ilaç bilgi kaynağındakiantimikrobiyal ilaçlar için olan doz önerilerininkarşılaştırılması amaçlanmaktadır.Gereç ve Yöntemler: Hacettepe Üniversitesi HastaneleriDahiliye Yoğun Bakım Üniteleri’nde sıklıkla kullanıldığıbelirlenen 25 antimikrobiyal ilacın (ampisilin, piperasilin/tazobaktam, seftriakson, sefepim, sefotaksim, meropenem,trimetoprim/sulfametoksazol, klaritromisin, tigesiklin, siprofloksasin,moksifloksasin, amikasin, vankomisin, teikoplanin,kolistin, metronidazol, amfoterisin B, kaspofungin, anidulafungin,flukonazol, vorikonazol, posakonazol, asiklovir,gansiklovir ve oseltamivir) en sık kullanılan 5 elektronik bilgikaynağında [The Sanford Guide to Antimicrobial Therapy,Micromedex® Solutions, Kidney Disease Program (KDP),Medscape ve UpToDate®] yer alan SRRT’deki ilaç doz önerileriklinik eczacılar tarafından karşılaştırılmıştır.Bulgular: Sanford, UpToDate® ve KDP bilgi kaynakları, Micromedex®ve Medscape’e göre SRRT’de ilaç dozları ile ilgilidaha fazla öneri içermektedir. Sadece Micromedex® ve UpToDate®kaynaklarında SRRT türüne yönelik doz önerileribulunmaktadır. UpToDate®, KDP, Micromedex® ve Sanfordönerilerinin bazılarında kaynak bilgisi verilmiştir. Bilgi kaynaklarıarasındaki farklılıklar en çok, piperasilin-tazobaktam,trimetoprim/sulfametoksazol, amikasin, vankomisin, kolistinve vorikonazol ilaçlarında saptanmıştır.Sonuç: Sürekli renal replasman tedavisinde ilaç kullanımınayönelik yararlanılan bir kaynakta yer alan doz önerileri “standart”olarak düşünülmemelidir. SRRT alan hastalarda antimikrobiyalilaç dozlamını değerlendiren az sayıda çalışmabulunduğu ve mevcut kaynakların önerileri arasında farklılıklargörülebileceği göz önünde tutulmalıdır. En uygun ilaçrejimini belirlemek için farklı kaynaklardan da yararlanmalıve hastanın klinik cevabı yakından izlenmelidir.

🔖

Cite This Article

DEMİRKAN, K., İSKİT, A. T., YALÇIN, N., EKİNCİOĞLU, A. B., SÜRMELİOĞLU, N., KELLECİ, B., KÖSELECİ, E. (2022). Drug Use in Continuous Renal Replacement Therapy and the Comparison of Electronic Drug Information Resources for Dose Adjustments. Dahili ve Cerrahi Bilimler Yoğun Bakım Dergisi, Cilt: 9 - Sayı: 1, 7–11. https://ajindex.com/articles/486526

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Karakoç E. Sürekli Renal Replasman Tedavileri. Yoğun Bakım Derg 2007; 7: 240-6.
  2. Matzke GR, Aronoff GR, Atkinson Jr AJ, et al. Drug Dosing Consideration in Patients With Acute and Chronic Kidney Disease. Kidney Int 2011; 80: 1122– 37. [CrossRef ] Awdishu L, Bouchard J. How to Optimize Drug Delivery in Renal Replacement Therapy. Semin Dial 2011; 24: 176-82. [CrossRef ] Böhler J, Donauer J, Keller F. Pharmacokinetic Principles During Continuous Renal Replacement Therapy: Drugs and Dosage. Kidney Int 1999; 56: 24-8. [CrossRef ] Churchwell MD, Mueller BA. Drug Dosing During Continuous Renal Replacement Therapy. Semin Dial 2009; 22: 185-8. [CrossRef ] Mahmoud SH. Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature. Clin Drug Investig 2017; 37: 7-23. [CrossRef ] Suh B, Craig WA, England AC, et al. Effects of Free Fatty Acids on Protein Binding of Antimicrobial Agents. J Infect Dis 1981; 143: 609-16. [CrossRef ] Susla GM. The impact of continuous renal replacement therapy on drug therapy. Clin Pharmacol Ther 2009; 86: 562–5. [CrossRef ] Gür D. Antibiyotikler ve İn-Vitro Parametreler. ANKEM Derg 2010; 24: 155-8. 10. Schetz M. Drug Dosing in Continuous Renal Replacement Therapy: General Rules. Curr Opin Crit Care 2007; 13: 645–51. [CrossRef ] Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45: 929–34. [CrossRef ] Dikmen Y. Renal Replasman Tedavisi: Ne Zaman, Nasıl, Nereye Kadar? Turk J Intense Care 2010; 8: 18-27.
  3. Oral M, Çakar Turhan KS. Renal replasman tedavisi sürekli mi, aralıklı mı uygulanmalı?. Turk J Intense Care 2010; 8: 28-37.
  4. Sungur M, Utaş C. Yoğun Bakım Ünitesindeki Devamlı Renal Replasman Tedavisi. Turk Neph Dial Transpl 2002; 2: 1-7.
  5. Kempke AP, Leino AS, Daneshvar F, et al. Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies. Crit Care Res Pract 2016; 2016: 3235765. [CrossRef ] Kroh UF. Drug administration in critically ill patients with acute renal failure. New Horiz 1995; 3: 748–59.
  6. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24: 362–79. [CrossRef ] Available from: http://www.yogunbakimdergisi.org/managete/fu_folder/2003-03/html/2003-3-3-182-188.htm
  7. Jiang SP, Zhu ZY, Wu XL, et al. Effectiveness of pharma